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Abstract: A one-pot regioselective method for the preparation
of 2-arylbenzoxazoles from N-arylbenzamides has been devel-
oped using iron(III)-catalyzed bromination of the aryl ring, fol-
lowed by copper(I)-catalyzed O-cyclization with the benzamide
side chain. In contrast, reaction of N-arylthiobenzamides with
N-bromosuccinimide and iron triflimide led directly to the isola-
tion of the corresponding 2-arylbenzothiazoles via intramolec-
ular C–S bond formation. Mechanistic and control experiments
Introduction
Benzannulated heterocycles such as benzoxazoles and benzo-
thiazoles are important structural motifs found in a wide range
of natural products and pharmaceutically active agents.[1] C2-
Substituted systems, particularly aryl derivatives, have been
shown to possess anticancer, antibacterial, antimicrobial or anti-
viral activity.[1] As a result of this biological and medicinal im-
portance, there have been significant efforts in developing
rapid and efficient syntheses of these heterocycles.[2,3] Tradi-
tional approaches include the reaction of 2-aminophenols and
2-aminothiophenols with carboxylic acid derivatives under
acidic, dehydrating conditions.[2] Another common approach in-
volves the reaction of 2-aminophenols and 2-aminothiophenols
with aldehydes, followed by oxidative cyclization of imine inter-
mediates.[2d]
More recently, transition metal-catalyzed methods involving
O- or S-cyclization of N-arylbenzamides and N-arylthiobenz-
amides have been reported. For example, ligand-assisted, cop-
per-catalyzed cyclization of N-haloaryl benzamides and thio-
benzamides at elevated temperatures have produced the corre-
sponding benzannulated heterocycles in good yields (Fig-
ure 1a).[4] To avoid the use of pre-activated, haloaryl systems,
direct transition metal catalyzed cyclization of N-arylbenz-
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suggest that in this case, bromination occurs at the sulfur atom,
resulting in a reactive intermediate that can undergo electro-
philic aromatic substitution and S-cyclization. The scope of both
processes was explored yielding a range of structural ana-
logues, including a pharmaceutically active compound for the
treatment of Duchenne muscular dystrophy and an affinity
agent of the amyloid-beta protein in Alzheimer's disease.
amides and N-arylthiobenzamides under oxidative conditions
has also been developed (Figure 1b).[5,6] Seminal work by Naga-
sawa and co-workers showed that benzoxazoles could be ac-
cessed directly from N-arylbenzamides using copper-catalysis
and oxygen,[5a,5b] while the groups of Doi[6a,6c] and Batey[6b]
used palladium catalyzed cyclization of N-arylthiobenzamides,
under oxidative conditions for the synthesis of benzothiazoles.
Further metal-mediated methods included an iron-catalyzed
procedure for the synthesis of benzothiazoles that used sodium
thiosulfate as the oxidant and was performed at lower tempera-
tures.[6d] Similar cyclizations using oxidants such as TEMPO,
oxone or oxygen, under photoredox,[7] electrochemical[8] or or-
ganocatalytic[9] conditions have also been described for the
preparation of these benzannulated heterocycles.
Figure 1. Metal-catalyzed synthesis of benzoxazoles and benzothiazoles.
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While these methods provide flexible access to these ring
systems, we were interested in developing processes that
avoided pre-activated haloaryl starting materials, strong oxid-
ants or precious transition metals. In recent years, we have re-
ported the use of the super Lewis acid, iron(III)-triflimide for the
activation of N-halosuccinimide reagents and the subsequent,
highly regioselective halogenation of aryl rings.[10] We have also
shown the combination of this halogenation reaction with cop-
per(I)-catalyzed Ullmann-type N-arylations, thereby converting
aryl C–H bonds to C–N bonds in a one-pot process.[11] An intra-
molecular version of this process has also been developed for
the preparation of indolines and dihydrobenzofurans.[12] Build-
ing on this research programme, we were interested in extend-
ing the scope of these one-pot processes for the rapid synthesis
of pharmaceutically relevant 2-arylbenzoxazoles and 2-aryl-
benzothiazoles. Herein, we now report the use of a one-pot
iron(III)-catalyzed bromination and copper(I)-catalyzed O-cycli-
zation of N-arylbenzamides for the preparation of 2-aryl-
benzoxazoles (Figure 1c). The reaction of iron(III)-triflimide and
NBS with N-arylthiobenzamides for the direct synthesis of 2-
arylbenzothiazoles is also described. As well as exploring the
scope of both reaction processes, the synthetic utility of these
transformations for the preparation of pharmaceutically impor-
tant targets is also demonstrated.
Results and Discussion
Initially, a series of N-arylbenzamides was prepared by the reac-
tion of anilines with aryl acid chlorides in the presence of tri-
ethylamine.[13] N-(3,4-Dimethoxyphenyl)benzamide (1a) was
used to optimize the one-pot process (Table 1). Investigation of
each step separately showed that the use of copper iodide
(10 mol-%), DMEDA (20 mol-%) and cesium carbonate at 130 °C
allowed efficient O-cyclization, however, the prior halogenation
step required optimization. An initial attempt, involving the
generation of iron triflimide from iron trichloride (5 mol-%) and
the ionic liquid, [BMIM]NTf2 (15 mol-%), for the activation of
N-iodosuccinimide (NIS) and subsequent reaction with 1a, re-
sulted in slow iodination and gave a 36 % yield of 2a after
copper-catalyzed O-cyclization (entry 1). It was proposed the
slow reaction of 1a with NIS was due to steric hindrance and
therefore, the smaller reagent, N-bromosuccinimide (NBS) was
investigated. Under the same conditions, this allowed faster hal-
ogenation and led to an improved overall yield of 2a (entry 2).
A solvent screen was then performed to investigate whether
improved solubility of 1a in alternative solvents might lead to
a more efficient bromination step. Issues with isolation of the
final product 2a resulted in a lower yield when using DMF as
the reaction solvent (entry 3). A combination of using toluene
and THF (5:1) as co-solvents and a slightly elevated reaction
temperature of 40 °C led to an improved yield of 51 % over the
two steps (entry 4). Finally, the use of toluene and acetonitrile
(5:1), resulted in clean and complete conversion to the bromin-
ated intermediate and the highest overall yield of 57 % for
benzoxazole 2a (entry 5).
Having developed an optimized one-pot bromination and O-
cyclization process, the scope of this transformation was explored
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Table 1. Optimization of the one-pot halogenation and O-cyclization of 1a.
Entry NXS[a] Solvent[b] Temp Time Yield
[°C] [h] [%][c]
1 NIS toluene r.t. 8 36
2 NBS toluene r.t. 4 46
3 NBS DMF r.t. 4 40
4[d] NBS toluene/THF 40 4 51
5[e] NBS toluene/MeCN 40 4 57
[a] One equivalent of NIS or NBS was used for each experiment. [b] Reactions
performed at 0.17 M. [c] Isolated yield of 2a. [d] Ratio of solvents was 5:1
(toluene/THF). [e] Ratio of solvents was 5:1 (toluene/MeCN).
for the preparation of various benzoxazoles (Scheme 1). Our pre-
vious studies in developing iron(III)-catalyzed halogenation of aryl
systems have shown that electron-rich, activating substituents
are required for this transformation to proceed.[10–12] Therefore,
this study focused on the one-pot halogenation and cyclization
of electron-rich N-arylbenzamides. Using N-(3,4-dimethoxy-
phenyl)benzamides (1a–1d) with a variety of substituents gave
the corresponding benzoxazoles (2a–2d) as single regioiso-
mers, in good overall yields (51–66 %). Higher yields were ob-
tained from the one-pot bromination and O-cyclization of
N-(3,4-methylenedioxyphenyl)benzamides 1e and 1f. As well as
the synthesis of benzoxazole 2e, this gave 2f, which has been
shown to have significant activity in a luciferase reporter assay
of murine H2K cells, a predictive screening process for identify-
ing compounds that have the potential for the treatment of
Duchenne muscular dystrophy.[14] The use of the one-pot proc-
ess with more demanding substrates was also explored. This
included the iron-catalyzed bromination and copper-catalyzed
O-cyclization of tri-substituted N-arylbenzamides 1g and 1h. As
expected, the greater steric hindrance associated with the
ortho,ortho-substituted aryl position required to undergo halo-
genation, resulted in isolation of benzoxazoles 2g and 2h in
slightly reduced yields under the standard conditions. Surpris-
ingly, less reactive aryl systems, bearing only one activating
group, were found to be effective substrates for the one-pot
process. N-Arylbenzamides 1i and 1j gave benzoxazoles 2i and
2j in 62 % and 72 % yields, respectively.
It should be noted that specific limitations were observed
with some classes of substrates. Lower yields were obtained for
mono-substituted N-arylbenzamides. For example, while N-
(3-methoxyphenyl)benzamide 1k underwent successful trans-
formation to benzoxazole 2k, competing bromination at the
4-position of the aryl ring meant that the target was isolated in
33 % yield (Scheme 1).[15] As mentioned above, electron-rich
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Scheme 1. Substrate scope for the synthesis of benzoxazoles. [a] Halogen-
ation step required 12 h.
arenes are required for efficient halogenation in these one-pot
processes. In this study, we investigated the electronic limita-
tion for the synthesis of benzoxazoles with a weakly activating
methyl substituent. Under the standard one-pot conditions, N-
arylbenzamide 1l required a significantly longer reaction time
for the halogenation step (12 h) and as a consequence of this,
benzoxazole 2l was isolated in 22 % yield. Finally, while the
focus of this study was the development of a process for the
preparation of pharmaceutically relevant 2-arylbenzoxazoles, a
2-alkyl analogue was investigated. N-(3,4-Dimethoxyphenyl)-
acetamide (1m) underwent rapid and regioselective bromin-
ation, however, attempted copper catalyzed O-cyclization gave
none of the corresponding benzoxazole 2m and instead, re-
turned 1m via protodecupration.
With an understanding of the scope and limitations of the
one-pot process for the synthesis of benzoxazoles, this ap-
proach was next investigated for the preparation of benzothi-
azoles. Initially, a number of the previously synthesized N-aryl-
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benzamides were converted into the corresponding N-aryl-
thiobenzamides by reaction with Lawesson's reagent.[13] Under
the optimized conditions for bromination of the N-arylbenz-
amides, N-(3,4-dimethoxyphenyl)thiobenzamide (3a) was then
subjected to the same iron(III)-triflimide catalyzed halogenation
step (Scheme 2). Investigation of this transformation by 1H NMR
spectroscopy surprisingly revealed direct synthesis of benzothi-
azole 4a. After a brief optimization study, which showed the
most favorable conditions were a 2 h reaction at 40 °C, benzo-
thiazole 4a was isolated in 54 % yield. The scope of this single
step, iron(III)-triflimide catalyzed S-cyclization was then ex-
plored with various N-(3,4-dimethoxyphenyl)thiobenzamides
(3a–3d) and N-(3,4-methylenedioxyphenyl)thiobenzamides
(3e–3f ). This gave 2-aryl-substituted benzothiazoles 4a–4f as
single regioisomers, in yields of 47–65 %. This included the
preparation of 2-(4′-fluorophenyl)-5,6-dimethoxy-1,3-benzothi-
azole (4d), which is a high affinity agent of the amyloid-beta
protein in Alzheimer's disease.[16] Lower yields again were
noted for sterically hindered trisubstituted substrates (4g, 36 %)
and, 2-alkyl analogues (4h, 17 %), in which a slower cyclization
reaction allowed competing aryl ring bromination.
Scheme 2. Substrate scope for the synthesis of benzothiazoles. [a] Dichloro-
methane was used as a co-solvent.
Based on the iron(III)-catalyzed activation of NBS, a mecha-
nism for benzothiazole formation was proposed (Scheme 3a).
In a similar fashion to the preparation of benzothiazoles by
S-cyclization of N-arylthiobenzamides using the Jacobson
method involving potassium ferricyanide[17] and the Huger-
schoff reaction with bromine,[18] we propose that the iron(III)
complexed NBS species results in activation of the sulfur atom,
yielding S-bromide intermediate 5. Following formation of 5,
the transformation is completed by an intramolecular electro-
philic aromatic substitution step. Such a mechanism accounts
for the lower yields observed for substrates such as 3i
(Scheme 3b), in which the less activated aryl ring undergoes
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electrophilic aromatic substitution more slowly, resulting in
moderate yield (37 %) of the corresponding benzothiazole 4i.
Further evidence for this mechanism was gained by the investi-
gation of non-activated substrates such as N-(4-methyl-
phenyl)thiobenzamide (3j). In this case, reaction of 3j under the
standard S-cyclization conditions returned only N-arylbenz-
amide 1l in 67 % yield. During this transformation, we believe
that N-arylthiobenzamide 3j is converted into the correspond-
ing S-bromide intermediate. As the less activated aryl ring is
not able to perform electrophilic aromatic substitution, the S-
bromide intermediate is instead hydrolyzed, generating N-aryl-
benzamide 1l.
Scheme 3. (a) Mechanism of iron(III) and NBS cyclization of N-arylthiobenz-
amides. (b) Mechanism elucidation experiments with N-arylthiobenzamides
3i and 3j.
Conclusions
In summary, two distinct methods for the synthesis of 2-aryl-
benzoxazoles and 2-arylbenzothiazoles have been developed
using iron(III)-triflimide activation of NBS. N-Arylbenzamides
were cyclized in a one-pot process using a regioselective
iron(III)-catalyzed bromination reaction, followed by a copper(I)-
catalyzed C–O bond forming process, while N-arylthiobenz-
amides were cyclized directly, by iron(III)-mediated bromination
of the thiobenzamide, followed by an intramolecular electro-
philic aromatic substitution reaction. The scope and limitations
of both processes were explored with a range of substrates,
leading to the synthesis of a small library of products, including
two pharmaceutically important compounds. It should be
noted that the single step C–S bond forming process is per-
formed under milder conditions than is normally used for this
type of cyclization and so generates these compounds very
cleanly. Current work is investigating further applications of
iron(III)-triflimide catalyzed aryl functionalization for the regio-
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selective synthesis of substituted arenes and benzannulated
heterocycles.
Experimental Section
All reagents and starting materials were obtained from commercial
sources and used as received unless otherwise stated. N-bromo-
succinimide was recrystallized from water and dried under high vac-
uum before use. All dry solvents were purified using a PureSolv 500
MD solvent purification system. All reactions were performed in
oven-dried glassware under an atmosphere of argon unless other-
wise stated. Brine refers to a saturated aqueous solution of sodium
chloride. Flash column chromatography was performed using silica
gel 60 (35–70 μm). Aluminium-backed plates pre-coated with silica
gel 60F254 were used for thin layer chromatography and were visu-
alized with a UV lamp or by staining with potassium permanganate
or ninhydrin. 1H NMR spectra were recorded on Bruker NMR spec-
trometers at either 400 or 500 MHz and data are reported as fol-
lows: chemical shifts in ppm relative to tetramethylsilane as the
internal standard, multiplicity (s = singlet, d = doublet, t = triplet,
q = quartet, m = multiplet or overlap of non-equivalent resonan-
ces). 13C NMR spectra were recorded on Bruker NMR spectrometers
at either 101 or 126 MHz and data are reported as follows: chemical
shift in ppm relative to tetramethylsilane or the solvent as internal
standard (CDCl3, δ = 77.0 ppm), multiplicity with respect to
hydrogen (deduced from DEPT experiments, C, CH, CH2 or CH3).
Assignments are based on 2-dimensional COSY, HSQC and HMBC
experiments. Infrared spectra were recorded on a FTIR spectrome-
ter; wavenumbers are indicated in cm–1. Mass spectra were re-
corded using electron impact or electrospray techniques. HRMS
spectra were recorded using a dual-focusing magnetic analyzer
mass spectrometer. Melting points were determined on a Gallen-
camp melting point apparatus.
2-Phenyl-5,6-dimethoxy-1,3-benzoxazole (2a):[19] Iron(III) chloride
(1.62 mg, 0.0100 mmol) was dissolved in 1-butyl-3-methylimid-
azolium bis(trifluoromethanesulfonyl)imide (8.70 μL, 0.0300 mmol)
and stirred for 0.5 h at room temperature and then added to a
suspension of N-bromosuccinimide (0.0360 g, 0.200 mmol) in tolu-
ene (0.5 mL). N-(3,4-Dimethoxyphenyl)benzamide (1a) (0.0510 g,
0.200 mmol) in toluene (0.5 mL) and acetonitrile (0.2 mL) was then
added and the mixture was stirred at 40 °C for 4 h. Upon completion
of the bromination step, the reaction mixture was cooled to room
temperature, diluted with toluene (1.0 mL) and cesium carbonate
(0.130 g, 0.400 mmol), copper(I) iodide (3.80 mg, 0.0200 mmol), N,N′-
dimethylethylenediamine (4.30 μL, 0.0400 mmol) and water (0.4 mL)
were added. The reaction mixture was degassed under argon for
0.1 h and then heated to 130 °C for 18 h. The reaction mixture was
then cooled to room temperature, diluted with ethyl acetate (10 mL)
and washed with 1 M aqueous sodium thiosulfate solution (10 mL).
The aqueous layer was extracted with ethyl acetate (3 × 10 mL) and
the combined organic layers were washed with brine (30 mL). The
organic phase was dried (MgSO4), filtered and concentrated in
vacuo. Purification by flash column chromatography (petroleum
ether/ethyl acetate, 7:3) gave 2-phenyl-5,6-dimethoxy-1,3-benzox-
azole (2a) (0.0286 g, 57 %) as a white solid. Mp 109–112 °C (lit.[19]
114–115 °C). 1H NMR (400 MHz, CDCl3): δ = 3.95 (s, 3H, OCH3), 3.96
(s, 3H, OCH3), 7.13 (s, 1H, 7-H), 7.25 (s, 1H, 4-H), 7.48–7.52 (m, 3H,
3′-H, 4′-H and 5′-H), 8.16–8.20 (m, 2H, 2′-H and 6′-H). 13C NMR
(101 MHz, CDCl3): δ = 56.5 (CH3), 56.5 (CH3), 94.4 (CH), 101.8 (CH),
127.0 (2 × CH), 127.5 (C), 128.9 (2 × CH), 130.9 (CH), 135.0 (C), 145.2
(C), 147.8 (C), 148.4 (C), 162.3 (C). MS (ESI) m/z (%): 278 (100) [M +
Na]+.
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2-(4′-Methoxyphenyl)-5,6-dimethoxy-1,3-benzoxazole (2b): 2-
(4′-Methoxyphenyl)-5,6-dimethoxy-1,3-benzoxazole (2b) was syn-
thesized as described for 2-phenyl-5,6-dimethoxy-1,3-benzoxazole
(2a) using 4′-methoxy-N-(3,4-dimethoxyphenyl)benzamide (1b)
(0.057 g, 0.20 mmol) in toluene (1.0 mL) and acetonitrile (0.4 mL).
The bromination step was carried out at 40 °C for 4 h and the
O-arylation step at 130 °C for 48 h. Purification by flash column
chromatography (hexane/ethyl acetate, 4:1) gave 2-(4′-methoxy-
phenyl)-5,6-dimethoxy-1,3-benzoxazole (2b) (0.030 g, 52 %) as a
light yellow solid. Mp 118–120 °C. IR (neat): ν˜max = 2928, 1605, 1481,
1250, 1219, 1128, 1057, 1018, 837. 1H NMR (500 MHz, CDCl3): δ =
3.88 (s, 3H, OCH3), 3.94 (s, 3H, OCH3), 3.95 (s, 3H, OCH3), 7.01 (d, J =
8.9 Hz, 2H, 3′-H and 5′-H), 7.11 (s, 1H, 7-H), 7.23 (s, 1H, 4-H), 8.11 (d,
J = 8.9 Hz, 2H, 2′-H and 6′-H). 13C NMR (101 MHz, CDCl3): δ = 55.4
(CH3), 56.4 (CH3), 56.5 (CH3), 94.3 (CH), 101.6 (CH), 114.3 (2 × CH),
120.1 (C), 128.7 (2 × CH), 135.0 (C), 145.0 (C), 147.6 (C), 148.0 (C),
161.8 (C), 162.4 (C). HRMS (ESI) m/z [M + Na]+ calcd. for
C16H15NNaO4 308.0893, found 308.0883.
2-(4′-Chlorophenyl)-5,6-dimethoxy-1,3-benzoxazole (2c): 2-(4′-
Chlorophenyl)-5,6-dimethoxy-1,3-benzoxazole (2c) was synthesized
as described for 2-phenyl-5,6-dimethoxy-1,3-benzoxazole (2a)
using 4′-chloro-N-(3,4-dimethoxyphenyl)benzamide (1c) (0.058 g,
0.20 mmol) in toluene (1.0 mL) and acetonitrile (0.2 mL). The brom-
ination step was carried out at 40 °C for 4 h and the O-arylation
step at 130 °C for 48 h. Purification by flash column chromatography
(hexane/ethyl acetate, 7:3) gave 2-(4′-chlorophenyl)-5,6-dimethoxy-
1,3-benzoxazole (2c) (0.038 g, 66 %) as a light yellow solid. Mp 160–
161 °C. IR (neat): ν˜max = 2928, 1481, 1159, 1134, 1007, 883, 824. 1H
NMR (500 MHz, CDCl3): δ = 3.95 (s, 3H, OCH3), 3.96 (s, 3H, OCH3),
7.11 (s, 1H, 7-H), 7.23 (s, 1H, 4-H), 7.46 (d, J = 8.7 Hz, 2H, 3′-H and
5′-H), 8.09 (d, J = 8.7 Hz, 2H, 2′-H and 6′-H). 13C NMR (101 MHz,
CDCl3): δ = 56.4 (CH3), 56.5 (CH3), 94.2 (CH), 101.7 (CH), 126.0 (C),
128.2 (2 × CH), 129.2 (2 × CH), 134.8 (C), 137.0 (C), 145.2 (C), 147.9
(C), 148.6 (C), 161.2 (C). HRMS (ESI) m/z [M + Na]+ calcd. for
C15H1235ClNNaO3 312.0398, found 312.0391.
2-(4′-Cyanophenyl)-5,6-dimethoxy-1,3-benzoxazole (2d): 2-(4′-
Cyanophenyl)-5,6-dimethoxy-1,3-benzoxazole (2d) was synthesized
as described for 2-phenyl-5,6-dimethoxy-1,3-benzoxazole (2a)
using 4′-cyano-N-(3,4-dimethoxyphenyl)benzamide (1d) (0.0565 g,
0.20 mmol) in toluene (1.0 mL) and acetonitrile (1.0 mL). The brom-
ination step was carried out at 40 °C for 4 h and the O-arylation
step at 130 °C for 48 h. Purification by flash column chromatography
(dichloromethane/ethyl acetate, 19:1) gave 2-(4′-cyanophenyl)-5,6-
dimethoxy-1,3-benzoxazole (2d) (0.028 g, 51 %) as a white solid. Mp
247–248 °C. IR (neat): ν˜max = 2968, 2220, 1481, 1329, 1273, 1192,
1161, 1134, 1003, 887, 839. 1H NMR (400 MHz, CDCl3): δ = 3.96 (s,
3H, OCH3), 3.98 (s, 3H, OCH3), 7.14 (s, 1H, 7-H), 7.26 (s, 1H, 4-H), 7.78
(d, J = 8.4 Hz, 2H, 3′-H and 5′-H), 8.26 (d, J = 8.4 Hz, 2H, 2′-H and
6′-H). 13C NMR (101 MHz, CDCl3): δ = 56.5 (CH3), 56.5 (CH3), 94.2
(CH), 101.8 (CH), 113.9 (C), 118.3 (C), 127.2 (2 × CH), 131.4 (C), 132.7
(2 × CH), 134.9 (C), 145.5 (C), 148.3 (C), 149.4 (C), 160.1 (C). HRMS
(EI) m/z [M]+ calcd. for C16H12N2O3 280.0848, found 280.0860.
2-Phenyl-5,6-methylenedioxy-1,3-benzoxazole (2e):[20] 2-Phenyl-
5,6-methylenedioxy-1,3-benzoxazole (2e) was synthesized as de-
scribed for 2-phenyl-5,6-dimethoxy-1,3-benzoxazole (2a) using N-
(3,4-methylenedioxyphenyl)benzamide (1e) (0.0513 g, 0.213 mmol)
in toluene (1.6 mL) and tetrahydrofuran (0.4 mL). The bromination
step was carried out at 40 °C for 3 h and the O-arylation step at
130 °C for 20 h. Purification by flash column chromatography (hex-
ane/diethyl ether, 19:1) gave 2-phenyl-5,6-methylenedioxy-1,3-
benzoxazole (2e) (0.0351 g, 69 %) as a white solid. Mp 142–143 °C
(lit.[20] 147–148 °C). 1H NMR (500 MHz, CDCl3): δ = 6.03 (s, 2H,
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OCH2O), 7.06 (s, 1H, 7-H), 7.17 (s, 1H, 4-H), 7.46–7.52 (m, 3H, 3′-H,
4′-H and 5′-H), 8.12–8.18 (m, 2H, 2′-H and 6′-H). 13C NMR (126 MHz,
CDCl3): δ = 92.6 (CH), 99.5 (CH), 101.7 (CH2), 126.9 (2 × CH), 127.4
(C), 128.9 (2 × CH), 130.9 (CH), 136.1 (C), 145.7 (C), 145.8 (C), 146.4
(C), 162.6 (C). MS (ESI) m/z (%): 262 (100) [M + Na]+.
2-(4′-Chlorophenyl)-5,6-methylenedioxy-1,3-benzoxazole (2f):[14]
2-(4′-Chlorophenyl)-5,6-methylenedioxy-1,3-benzoxazole (2f ) was
synthesized as described for 2-phenyl-5,6-dimethoxy-1,3-benzox-
azole (2a) using 4′-chloro-N-(3,4-methylenedioxyphenyl)benzamide
(1f ) (0.055 g, 0.20 mmol) in toluene (1.0 mL) and acetonitrile (1.0 mL).
The bromination step was carried out at 40 °C for 3 h and the O-
arylation step at 130 °C for 24 h. Purification by flash column chroma-
tography (dichloromethane/hexane, 7:3) gave 2-(4′-chlorophenyl)-
5,6-methylenedioxy-1,3-benzoxazole (2f ) (0.0412 g, 75 %) as a white
solid. Spectroscopic data were consistent with the literature.[14] Mp
252–254 °C. 1H NMR (500 MHz, [D6]DMSO): δ = 6.13 (s, 2H, OCH2O),
7.36 (s, 1H, 7-H), 7.49 (s, 1H, 4-H), 7.65 (d, J = 8.6 Hz, 2H, 3′-H and
5′-H), 8.10 (d, J = 8.6 Hz, 2H, 2′-H and 6′-H). 13C NMR (126 MHz,
[D6]DMSO): δ = 93.5 (CH2), 99.7 (CH), 102.4 (CH), 126.0 (C), 128.7
(2 × CH), 129.9 (2 × CH), 135.8 (C), 136.4 (C), 145.9 (C), 146.1 (C),
146.9 (C), 161.2 (C). MS (EI) m/z (%): 273 (100) [M]+.
2-Phenyl-5,6,7-trimethoxy-1,3-benzoxazole (2g): 2-Phenyl-5,6,7-
trimethoxy-1,3-benzoxazole (2g) was synthesized as described for
2-phenyl-5,6-dimethoxy-1,3-benzoxazole (2a) using N-(3,4,5-tri-
methoxyphenyl)benzamide (1g) (0.072 g, 0.25 mmol). The bromin-
ation step was carried out at 40 °C for 3 h and the O-arylation step
at 130 °C for 16 h. Purification by flash column chromatography
(hexane/ethyl acetate, 7:3) gave 2-phenyl-5,6,7-trimethoxy-1,3-
benzoxazole (2g) (0.030 g, 42 %) as a brown solid. Mp 56–57 °C. IR
(neat): ν˜max = 2947, 1601, 1557, 1487, 1458, 1421, 1123, 1038, 685.
1H NMR (400 MHz, CDCl3): δ = 3.92 (s, 3H, OCH3), 3.92 (s, 3H, OCH3),
4.31 (s, 3H, OCH3), 6.98 (s, 1H, 4-H), 7.49–7.55 (m, 3H, 3′-H, 4′-H and
5′-H), 8.17–8.23 (m, 2H, 2′-H and 6′-H). 13C NMR (101 MHz, CDCl3):
δ = 56.5 (CH3), 60.5 (CH3), 61.6 (CH3), 96.0 (CH), 127.1 (C), 127.3 (2 ×
CH), 128.9 (2 × CH), 131.3 (CH), 136.2 (C), 138.4 (C), 138.7 (C), 138.7
(C), 152.0 (C), 162.9 (C). HRMS (ESI) m/z [M + Na]+ calcd. for
C16H15NNaO4 308.0893, found 308.0886.
2-(4′-Fluorophenyl)-5,6,7-trimethoxy-1,3-benzoxazole (2h): 2-
(4′-Fluorophenyl)-5,6,7-trimethoxy-1,3-benzoxazole (2h) was syn-
thesized as described for 2-phenyl-5,6-dimethoxy-1,3-benzoxazole
(2a) starting from 4′-fluoro-N-(3,4,5-trimethoxyphenyl)benzamide
(1h) (0.076 g, 0.25 mmol). The bromination step was carried out at
40 °C for 3 h and the O-arylation step at 130 °C for 16 h. Purification
by flash column chromatography (hexane/ethyl acetate, 7:3) gave
2-(4′-fluorophenyl)-5,6,7-trimethoxy-1,3-benzoxazole (2h) (0.034 g,
45 %) as a white solid. Mp 89–90 °C. IR (neat): ν˜max = 2940, 1601,
1498, 1462, 1423, 1192, 1138, 1040, 1011, 849, 791. 1H NMR
(400 MHz, CDCl3): δ = 3.92 (s, 3H, OCH3), 3.92 (s, 3H, OCH3), 4.29 (s,
3H, OCH3), 6.96 (s, 1H, 4-H), 7.20 (t, J = 8.8 Hz, 2H, 3′-H, and 5′-H),
8.16–8.23 (m, 2H, 2′-H and 6′-H). 13C NMR (101 MHz, CDCl3): δ =
56.5 (CH3), 60.5 (CH3), 61.6 (CH3), 96.0 (CH), 116.2 (d, 2JCF = 22.3 Hz,
2 × CH), 123.5 (d, 4JCF = 3.2 Hz, C), 129.5 (d, 3JCF = 8.9 Hz, 2 × CH),
136.3 (C), 138.5 (C), 138.7 (C), 138.8 (C), 152.1 (C), 162.1 (C), 164.7
(d, 1JCF = 254.0 Hz, C). HRMS (ESI) m/z [M + Na]+ calcd. for
C16H14FNNaO4 326.0799, found 326.0793.
2-Phenyl-5-methoxy-6-methyl-1,3-benzoxazole (2i):[21] 2-Phenyl-
5-methoxy-6-methyl-1,3-benzoxazole (2i) was synthesized as de-
scribed for 2-phenyl-5,6-dimethoxy-1,3-benzoxazole (2a) using N-
(3-methoxy-4-methylphenyl)benzamide (1i) (0.068 g, 0.28 mmol) in
toluene (1.8 mL) and acetonitrile (0.2 mL). The bromination step
was carried out at 40 °C for 3 h and the O-arylation step at 130 °C
for 22 h. Purification by flash column chromatography (hexane/
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ethyl acetate, 9:1) gave 2-phenyl-5-methoxy-6-methyl-1,3-benzox-
azole (2i) (0.042 g, 62 %) as a white solid. Spectroscopic data were
consistent with the literature.[21] Mp 137–138 °C. 1H NMR (500 MHz,
CDCl3): δ = 2.34 (s, 3H, 6-CH3), 3.89 (s, 3H, OCH3), 7.18 (s, 1H, 4-H),
7.33 (s, 1H, 7-H), 7.47–7.53 (m, 3H, 3′-H, 4′-H and 5′-H), 8.17–8.24
(m, 2H, 2′-H and 6′-H). 13C NMR (101 MHz, CDCl3): δ = 17.2 (CH3),
55.8 (CH3), 100.4 (CH), 111.6 (CH), 125.3 (C), 127.3 (2 × CH), 127.5
(C), 128.9 (2 × CH), 131.1 (CH), 140.7 (C), 145.0 (C), 155.7 (C), 162.7
(C). MS (ESI) m/z (%): 262 (100) [M + Na]+.
2-(4′-Chlorophenyl)-5-methoxy-6-methyl-1,3-benzoxazole (2j):
2-(4′-Chlorophenyl)-5-methoxy-6-methyl-1,3-benzoxazole (2j) was
synthesized as described for 2-phenyl-5,6-dimethoxy-1,3-benzox-
azole (2a) using 4′-chloro-N-(3-methoxy-4-methylphenyl)benz-
amide (1j) (0.070 g, 0.25 mmol) in toluene (2.5 mL) and tetrahydro-
furan (1.0 mL). The bromination step was carried out at 40 °C for
3 h and the O-arylation step at 130 °C for 18 h. Purification by flash
column chromatography (hexane/diethyl ether, 19:1) gave 2-(4′-
chlorophenyl)-5-methoxy-6-methyl-1,3-benzoxazole (2j) (0.050 g,
72 %) as a white solid. Mp 141–143 °C. IR (neat): ν˜max = 2926, 1597,
1468, 1402, 1271, 1196, 1155, 1057, 826. 1H NMR (400 MHz, CDCl3):
δ = 2.33 (s, 3H, 6-CH3), 3.88 (s, 3H, OCH3), 7.15 (s, 1H, 4-H), 7.30 (s,
1H, 7-H), 7.44 (d, J = 8.8 Hz, 2H, 3′-H and 5′-H), 8.10 (d, J = 8.8 Hz,
2H, 2′-H and 6′-H). 13C NMR (101 MHz, CDCl3): δ = 17.2 (CH3), 55.8
(CH3), 100.4 (CH), 111.5 (CH), 125.7 (C), 126.0 (C), 128.5 (2 × CH),
129.2 (2 × CH), 137.2 (C), 140.6 (C), 145.0 (C), 155.8 (C), 161.7 (C).
HRMS (ESI) m/z [M + Na]+ calcd. for C15H1235ClNNaO2 296.0449,
found 296.0443.
2-Phenyl-5-methoxy-1,3-benzoxazole (2k):[20] 2-Phenyl-5-meth-
oxy-1,3-benzoxazole (2k) was synthesized as described for 2-
phenyl-5,6-dimethoxy-1,3-benzoxazole (2a) using N-(3-methoxy-
phenyl)benzamide (1k) (0.0460 g, 0.200 mmol). The bromination
step was carried out at 40 °C for 3 h and the O-arylation step at
130 °C for 24 h. Purification by flash column chromatography (hex-
ane/diethyl ether, 4:1) gave 2-phenyl-5-methoxy-1,3-benzoxazole
(2k) (0.0150 g, 33 %) as a white solid. Mp 75–77 °C (lit.[20] 79–80 °C).
1H NMR (500 MHz, CDCl3): δ = 3.88 (s, 3H, OCH3), 6.95 (dd, J = 9.0,
2.6 Hz, 1H, 6-H), 7.27 (d, J = 2.6 Hz, 1H, 4-H), 7.46 (d, J = 9.0 Hz, 1H,
7-H), 7.49–7.55 (m, 3H, 3′-H, 4′-H and 5′-H), 8.20–8.26 (m, 2H, 2′-H
and 6′-H). 13C NMR (126 MHz, CDCl3): δ = 56.0 (CH3), 102.9 (CH),
110.7 (CH), 113.7 (CH), 127.3 (C), 127.5 (2 × CH), 128.9 (2 × CH),
131.4 (CH), 143.0 (C), 145.4 (C), 157.4 (C), 163.8 (C). MS (ESI) m/z (%):
248 (100) [M + Na]+.
2-Phenyl-6-methyl-1,3-benzoxazole (2l):[22] 2-Phenyl-6-methyl-
1,3-benzoxazole (2l) was synthesized as described for 2-phenyl-5,6-
dimethoxy-1,3-benzoxazole (2a) using N-(p-tolyl)benzamide (1l)
(0.0530 g, 0.250 mmol). The bromination step was carried out at
40 °C for 12 h and the O-arylation step at 130 °C for 24 h. Purifica-
tion by flash column chromatography (hexane/ethyl acetate, 9:1)
gave 2-phenyl-6-methyl-1,3-benzoxazole (2l) (0.0163 g, 22 %) as a
white solid. Mp 90–92 °C (lit.[22] 93 °C); 1H NMR (400 MHz, CDCl3):
δ = 2.50 (s, 3H, 6-CH3), 7.16 (d, J = 8.0 Hz, 1H, 5-H), 7.38 (s, 1H,
7-H), 7.49–7.55 (m, 3H, 3′-H, 4′-H and 5′-H), 7.64 (d, J = 8.0 Hz, 1H,
4-H), 8.20–8.26 (m, 2H, 2′-H and 6′-H). 13C NMR (101 MHz, CDCl3):
δ = 21.8 (CH3), 110.8 (CH), 119.4 (CH), 125.8 (CH), 127.4 (C), 127.5
(2 × CH), 128.9 (2 × CH), 131.3 (CH), 135.6 (C), 139.9 (C), 151.1 (C),
162.6 (C). MS (ESI) m/z (%): 210 (100) [M + H+].
2-Phenyl-5,6-dimethoxy-1,3-benzothiazole (4a):[14] Iron(III) chlor-
ide (1.0 mg, 0.0060 mmol) was dissolved in 1-butyl-3-methylimidaz-
olium bis(trifluoromethanesulfonyl)imide (5.2 μL, 0.018 mmol) and
stirred for 0.5 h at room temperature and then added to a solution
of N-bromosuccinimide (0.025 g, 0.14 mmol) in acetonitrile (1.0 mL).
N-(3,4-Dimethoxyphenyl)thiobenzamide (3a) (0.036 g, 0.12 mmol)
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in acetonitrile (2.0 mL) was then added and the mixture was stirred
at 40 °C for 2 h. The reaction mixture was then cooled to room
temperature, diluted with ethyl acetate (20 mL) and washed with
1 M aqueous sodium thiosulfate solution (20 mL). The aqueous layer
was extracted with ethyl acetate (3 × 20 mL) and the combined
organic layers were washed with brine (50 mL). The organic phase
was dried (MgSO4), filtered and concentrated in vacuo. Purification
by flash column chromatography (hexane/ethyl acetate, 9:1 to 4:1)
then recrystallization from hot acetonitrile gave 2-phenyl-5,6-di-
methoxy-1,3-benzothiazole (4a) (0.016 g, 54 %) as a yellow solid.
Mp 123–125 °C (lit.[14] 127–129 °C). 1H NMR (500 MHz, CDCl3): δ =
3.97 (s, 3H, OCH3), 3.99 (s, 3H, OCH3), 7.31 (s, 1H, 7-H), 7.43–7.50 (m,
3H, 3′-H, 4′-H and 5′-H), 7.56 (s, 1H, 4-H), 8.01–8.05 (m, 2H, 2′-H and
6′-H). 13C NMR (126 MHz, CDCl3): δ = 56.1 (CH3), 56.3 (CH3), 102.5
(CH), 104.8 (CH), 127.0 (2 × CH), 127.1 (C), 129.0 (2 × CH), 130.4 (CH),
133.8 (C), 148.5 (C), 148.6 (C), 149.5 (C), 166.3 (C). MS (ESI) m/z (%):
272 (100) [M + H]+.
2-(4′-Methoxyphenyl)-5,6-dimethoxy-1,3-benzothiazole (4b):[23]
2-(4′-Methoxyphenyl)-5,6-dimethoxy-1,3-benzothiazole (4b) was
synthesized as described for 2-phenyl-5,6-dimethoxy-1,3-benzothi-
azole (4a) using 4′-methoxy-N-(3,4-dimethoxyphenyl)thiobenzam-
ide (3b) (0.0607 g, 0.200 mmol) in acetonitrile (2.6 mL) and dichloro-
methane (0.4 mL). The yellow precipitate was collected, washed
with aqueous 1 M sodium thiosulfate solution (5 mL) and water
(10 mL). Recrystallization from hot acetonitrile gave 2-(4′-methoxy-
phenyl)-5,6-dimethoxy-1,3-benzothiazole (4b) (0.033 g, 55 %) as a
yellow solid. Mp 163–165 °C (lit.[23] 159–160 °C). 1H NMR (500 MHz,
CDCl3): δ = 3.87 (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 3.98 (s, 3H, OCH3),
6.98 (d, J = 8.9 Hz, 2H, 3′-H and 5′-H), 7.28 (s, 1H, 7-H), 7.52 (s, 1H,
4-H), 7.97 (d, J = 8.9 Hz, 2H, 2′-H and 6′-H). 13C NMR (126 MHz,
CDCl3): δ = 55.4 (CH3), 56.1 (CH3), 56.3 (CH3), 102.6 (CH), 104.6 (CH),
114.3 (2 × CH), 126.7 (C), 126.7 (C), 128.5 (2 × CH), 148.3 (C), 148.6
(C), 149.4 (C), 161.5 (C), 166.2 (C). MS (EI) m/z (%): 301 (100) [M]+,
286 (30), 258 (16), 215 (12), 151 (9), 125 (7), 82 (8).
2-(4′-Chlorophenyl)-5,6-dimethoxy-1,3-benzothiazole (4c): 2-(4′-
Chlorophenyl)-5,6-dimethoxy-1,3-benzothiazole (4c) was synthe-
sized as described for 2-phenyl-5,6-dimethoxy-1,3-benzothiazole
(4a) using 4′-chloro-N-(3,4-dimethoxyphenyl)thiobenzamide (3c)
(0.0363 g, 0.120 mmol) in acetonitrile (2.0 mL) and dichloromethane
(0.2 mL). Purification by flash column chromatography (hexane/
ethyl acetate, 7:3), followed by recrystallization from hot acetonitrile
gave 2-(4′-chlorophenyl)-5,6-dimethoxy-1,3-benzothiazole (4c)
(0.0214 g, 59 %) as a white solid. Mp 194–196 °C. IR (neat): ν˜max =
2959, 1510, 1466, 1433, 1290, 1244, 1221, 1161, 1001, 835. 1H NMR
(500 MHz, CDCl3): δ = 3.97 (s, 3H, OCH3), 3.98 (s, 3H, OCH3), 7.29 (s,
1H, 7-H), 7.44 (d, J = 8.5 Hz, 2H, 3′-H and 5′-H), 7.53 (s, 1H, 4-H),
7.95 (d, J = 8.5 Hz, 2H, 2′-H and 6′-H). 13C NMR (126 MHz, CDCl3)
56.1 (CH3), 56.3 (CH3), 102.4 (CH), 104.7 (CH), 127.1 (C), 128.2 (2 ×
CH), 129.2 (2 × CH), 132.4 (C), 136.4 (C), 148.5 (C), 148.8 (C), 149.6
(C), 164.7 (C). HRMS (ESI) m/z [M + Na]+ calcd. for C15H1235ClNNaO2S
328.0169, found 328.0158.
2-(4′-Fluorophenyl)-5,6-dimethoxy-1,3-benzothiazole (4d): 2-
(4′-Fluorophenyl)-5,6-dimethoxy-1,3-benzothiazole (4d) was synthe-
sized as described for 2-phenyl-5,6-dimethoxy-1,3-benzothiazole
(4a) using 4′-fluoro-N-(3,4-dimethoxyphenyl)thiobenzamide (3d)
(0.0583 g, 0.200 mmol). Purification by flash column chromatogra-
phy (dichloromethane/hexane, 9:3 to dichloromethane), followed
by recrystallization from hot acetonitrile gave 2-(4′-fluorophenyl)-
5,6-dimethoxy-1,3-benzothiazole (4d) (0.0317 g, 55 %) as a white
solid. Mp 146–148 °C. IR (neat): ν˜max = 2936, 1520, 1468, 1435, 1285,
1219, 1155, 999, 837. 1H NMR (500 MHz, CDCl3): δ = 3.98 (s, 3H,
OCH3), 3.99 (s, 3H, OCH3), 7.16 (t, J = 8.6 Hz, 2H, 3′-H and 5′-H), 7.30
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(s, 1H, 7-H), 7.54 (s, 1H, 4-H), 7.98–8.05 (m, 2H, 2′-H and 6′-H). 13C
NMR (126 MHz, CDCl3): δ = 56.1 (CH3), 56.4 (CH3), 102.5 (CH), 104.7
(CH), 116.1 (d, 2JCF = 22.2 Hz, 2 × CH), 127.1 (C), 128.9 (d, 3JCF =
8.8 Hz, 2 × CH), 130.2 (d, 4JCF = 3.4 Hz, C), 148.5 (C), 148.7 (C), 149.6
(C), 164.1 (d, 1JCF = 252.0 Hz, C), 165.0 (C). HRMS (ESI) m/z [M + Na]+
calcd. for C15H12FNNaO2S 312.0465, found 312.0461.
2-Phenyl-5,6-methylenedioxy-1,3-benzothiazole (4e): 2-Phenyl-
5,6-methylenedioxy-1,3-benzothiazole (4e) was synthesized as
described for 2-phenyl-5,6-dimethoxy-1,3-benzothiazole (4a) using
N-(3,4-methylenedioxyphenyl)thiobenzamide (3e) (0.0315 g,
0.122 mmol). Purification by flash column chromatography (hexane/
diethyl ether, 9:1) gave 2-phenyl-5,6-methylenedioxy-1,3-benzothi-
azole (4e) (0.0148 g, 47 %) as a white solid. Mp 160–161 °C. IR (neat):
ν˜max = 2924, 1456, 1441, 1279, 1190, 1043, 945, 876, 833, 756. 1H
NMR (500 MHz, CDCl3): δ = 5.98 (s, 2H, OCH2O), 7.17 (s, 1H, 7-H),
7.36–7.42 (m, 4H, 4-H, 3′-H, 4′-H and 5′-H), 7.91–7.95 (m, 2H, 2′-H
and 6′-H). 13C NMR (126 MHz, CDCl3): δ = 100.2 (CH), 101.8 (CH2),
102.7 (CH), 127.0 (2 × CH), 128.3 (C), 129.0 (2 × CH), 130.4 (CH),
133.8 (C), 146.9 (C), 148.0 (C), 149.3 (C), 166.4 (C). HRMS (ESI) m/z
[M + Na]+ calcd. for C14H10NO2S 256.0427, found 256.0428.
2-(4′-Chlorophenyl)-5,6-methylenedioxy-1,3-benzothiazole (4f):
2-(4′-Chlorophenyl)-5,6-methylenedioxy-1,3-benzothiazole (4f ) was
synthesized as described for 2-phenyl-5,6-dimethoxy-1,3-benzothi-
azole (4a) using 4′-chloro-N-(3,4-methylenedioxyphenyl)thio-
benzamide (3f ) (0.0425 g, 0.146 mmol) in acetonitrile (2.0 mL) and
dichloromethane (0.5 mL). Purification by recrystallization from hot
acetonitrile gave 2-(4′-chlorophenyl)-5,6-methylenedioxy-1,3-
benzothiazole (4f ) (0.0274 g, 65 %) as a white solid. Mp 220–222 °C.
IR (neat): ν˜max = 2897, 1506, 1456, 1285, 1090, 941, 878, 833, 824.
1H NMR (500 MHz, CDCl3): δ = 6.07 (s, 2H, OCH2O), 7.25 (s, 1H, 7-
H), 7.44 (d, J = 8.6 Hz, 2H, 3′-H and 5′-H), 7.46 (s, 1H, 4-H), 7.94 (d,
J = 8.6 Hz, 2H, 2′-H and 6′-H). 13C NMR (126 MHz, CDCl3): δ = 100.2
(CH), 101.9 (CH2), 102.7 (CH), 128.1 (2 × CH), 128.3 (C), 129.2 (2 ×
CH), 132.3 (C), 136.4 (C), 147.1 (C), 148.2 (C), 149.2 (C), 164.9 (C).
HRMS (ESI) m/z [M + H]+ calcd. for C14H835ClNNaO2S 311.9856,
found 311.9851.
2-Phenyl-5,6,7-trimethoxy-1,3-benzothiazole (4g):[24] 2-Phenyl-
5,6,7-trimethoxy-1,3-benzothiazole (4g) was synthesized as de-
scribed for 2-phenyl-5,6-dimethoxy-1,3-benzothiazole (4a) us-
ing N-(3,4,5-trimethoxyphenyl)thiobenzamide (3g) (0.0440 g,
0.145 mmol). Purification by flash column chromatography (di-
chloromethane/hexane, 7:3 to 9:1) gave 2-phenyl-5,6,7-trimethoxy-
1,3-benzothiazole (4g) (0.0156 g, 36 %) as a white solid. Mp 65–
67 °C (lit.[24] 61–63 °C). 1H NMR (500 MHz, CDCl3): δ = 3.94 (s, 3H,
OCH3), 3.96 (s, 3H, OCH3), 4.11 (s, 3H, OCH3), 7.36 (s, 1H, 4-H), 7.45–
7.51 (m, 3H, 3′-H, 4′-H and 5′-H), 8.02–8.07 (m, 2H, 2′-H and 6′-H).
13C NMR (126 MHz, CDCl3): δ = 56.3 (CH3), 60.6 (CH3), 61.5 (CH3),
100.8 (CH), 120.3 (C), 127.2 (2 × CH), 129.0 (2 × CH), 130.7 (CH),
133.7 (C), 139.8 (C), 146.8 (C), 150.5 (C), 154.0 (C), 168.0 (C). MS (ESI)
m/z (%): 324 (100) [M + Na]+.
2-Methyl-5,6-dimethoxy-1,3-benzothiazole (4h): 2-Methyl-
5,6-dimethoxy-1,3-benzothiazole (4h) was synthesized as described
for 2-phenyl-5,6-dimethoxy-1,3-benzothiazole (4a) using N-(3,4-di-
methoxyphenyl)thioacetamide (3h) (0.0423 g, 0.200 mmol). Purifica-
tion by flash column chromatography (dichloromethane/ethyl acet-
ate, 9:1) gave 2-methyl-5,6-dimethoxy-1,3-benzothiazole (4h)
(0.00710 g, 17 %) as a light-yellow oil. IR (neat) ν˜max = 2938, 1479,
1464, 1285, 1223, 1200, 1159, 1061, 831. 1H NMR (500 MHz, CDCl3):
δ = 2.79 (s, 3H, 2-CH3), 3.94 (s, 3H, OCH3), 3.95 (s, 3H, OCH3), 7.24
(s, 1H, 7-H), 7.44 (s, 1H, 4-H). 13C NMR (126 MHz, CDCl3): δ = 19.9
(CH3), 56.1 (CH3), 56.3 (CH3), 102.5 (CH), 104.3 (CH), 127.2 (C), 147.6
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(C), 148.1 (C), 149.1 (C), 165.0 (C). HRMS (ESI) m/z [M + H]+ calcd.
for C10H12NO2S 210.0583, found 210.0587.
2-Phenyl-5-methoxy-6-methyl-1,3-benzothiazole (4i): 2-Phenyl-
5-methoxy-6-methyl-1,3-benzothiazole (4i) was synthesized as
described for 2-phenyl-5,6-dimethoxy-1,3-benzothiazole (4a) using
N-(3-methoxy-4-methylphenyl)thiobenzamide (3i) (0.0646 g,
0.250 mmol). Purification by flash column chromatography (hexane/
dichloromethane, 1:1) gave 2-phenyl-5-methoxy-6-methyl-1,3-
benzothiazole (4i) (0.0238 g, 37 %) as a yellow solid. Mp 156–157 °C.
IR (neat): ν˜max = 3001, 2970, 1456, 1445, 1279, 1244, 1186, 1150,
1063, 1007, 997, 826, 760, 687. 1H NMR (500 MHz, CDCl3): δ = 2.34
(s, 3H, 6-CH3), 3.93 (s, 3H, OCH3), 7.44–7.50 (m, 3H, 3′-H, 4′-H and
5′-H), 7.51 (s, 1H, 4-H), 7.60 (s, 1H, 7-H), 8.03–8.08 (m, 2H, 2′-H and
6′-H). 13C NMR (126 MHz, CDCl3): δ = 16.9 (CH3), 55.6 (CH3), 103.4
(CH), 121.9 (CH), 126.4 (C), 126.4 (C), 127.2 (2 × CH), 129.0 (2 × CH),
130.6 (CH), 133.9 (C), 153.7 (C), 157.5 (C), 167.7 (C). HRMS (ESI) m/z
[M + H]+ calcd. for C15H14NOS 256.0791, found 256.0788.
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